CN101835476B - 作为受损伤口愈合组合物的抗连接蛋白多核苷酸 - Google Patents

作为受损伤口愈合组合物的抗连接蛋白多核苷酸 Download PDF

Info

Publication number
CN101835476B
CN101835476B CN200780051207.XA CN200780051207A CN101835476B CN 101835476 B CN101835476 B CN 101835476B CN 200780051207 A CN200780051207 A CN 200780051207A CN 101835476 B CN101835476 B CN 101835476B
Authority
CN
China
Prior art keywords
connexin
polynucleotide
wound
ulcers
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780051207.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101835476A (zh
Inventor
戴维·L·贝克尔
科林·R·格林
布拉德福德·J·杜夫特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Treatment Co Ltd
Original Assignee
CoDa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CoDa Therapeutics Inc filed Critical CoDa Therapeutics Inc
Priority to CN201310392821.XA priority Critical patent/CN103520197B/zh
Publication of CN101835476A publication Critical patent/CN101835476A/zh
Application granted granted Critical
Publication of CN101835476B publication Critical patent/CN101835476B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200780051207.XA 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸 Expired - Fee Related CN101835476B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310392821.XA CN103520197B (zh) 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87440406P 2006-12-11 2006-12-11
US60/874,404 2006-12-11
PCT/US2007/025446 WO2008073479A2 (en) 2006-12-11 2007-12-11 Anticonnexin polynucleotides as impaired wound healing compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310392821.XA Division CN103520197B (zh) 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸

Publications (2)

Publication Number Publication Date
CN101835476A CN101835476A (zh) 2010-09-15
CN101835476B true CN101835476B (zh) 2016-08-17

Family

ID=39386432

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780051207.XA Expired - Fee Related CN101835476B (zh) 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
CN201310392821.XA Expired - Fee Related CN103520197B (zh) 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310392821.XA Expired - Fee Related CN103520197B (zh) 2006-12-11 2007-12-11 作为受损伤口愈合组合物的抗连接蛋白多核苷酸

Country Status (15)

Country Link
US (5) US8063023B2 (enExample)
EP (3) EP2543378A1 (enExample)
JP (3) JP5431949B2 (enExample)
KR (1) KR101521306B1 (enExample)
CN (2) CN101835476B (enExample)
AU (1) AU2007333535B2 (enExample)
BR (1) BRPI0721094A2 (enExample)
CA (1) CA2672220A1 (enExample)
DK (1) DK2101791T3 (enExample)
ES (1) ES2527131T3 (enExample)
PL (1) PL2101791T3 (enExample)
PT (1) PT2101791E (enExample)
RU (1) RU2521329C2 (enExample)
SI (1) SI2101791T1 (enExample)
WO (1) WO2008073479A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5964538B2 (ja) 2005-02-03 2016-08-03 コーダ セラピューティクス， インコーポレイテッド 抗コネキシン化合物およびそれらの使用
US8247384B2 (en) 2006-11-15 2012-08-21 Coda Therapeutics, Inc. Methods and compositions for wound healing
CN101835476B (zh) 2006-12-11 2016-08-17 科达治疗公司 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
EP2628747A1 (en) * 2007-12-11 2013-08-21 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
CN101970663A (zh) * 2007-12-11 2011-02-09 科达治疗公司 受损伤口愈合的组合物和治疗
AU2008343756A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
AU2008343841A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of connexin43 for treatment of fibrotic conditions
NZ612533A (en) * 2010-12-06 2015-03-27 Univ British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing
GB201117538D0 (en) 2011-10-11 2011-11-23 Royal Veterinary College The Methods
CN104271142B (zh) 2012-03-01 2017-07-04 福斯特斯特林研究公司 含有α连接蛋白C‑末端(ACT)肽的局部凝胶
WO2013148736A1 (en) * 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
US9156896B2 (en) * 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
WO2015139047A2 (en) * 2014-03-14 2015-09-17 Coda Therapeutics Treatment of resistant lesions
CA2958879A1 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
CN108367017A (zh) * 2015-08-13 2018-08-03 索马根尼科斯公司 用于伤口愈合的短小发夹rna与微rna的组合物以及方法
US11096832B2 (en) * 2016-09-27 2021-08-24 Smith & Nephew Plc Wound closure devices with dissolvable portions
CN111201247A (zh) 2017-04-28 2020-05-26 奥克兰联合服务有限公司 治疗方法和新颖构建体
CN108588075A (zh) * 2018-05-03 2018-09-28 天德悦（北京）生物科技有限责任公司 人Cx43基因干扰序列、shRNA-Cx43病毒及低表达Cx43蛋白的细胞系
JP2023546757A (ja) 2020-10-22 2023-11-07 シークエル・バイオ・インコーポレイテッド ペプチド製剤および眼科におけるその使用
RU2754383C1 (ru) * 2020-12-07 2021-09-01 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) Способ лечения неинфицированного послеоперационного раневого дефекта стопы при отсутствии признаков критической ишемии конечности у больных с нейропатической и нейроишемической формой синдрома диабетической стопы

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0539594Y2 (enExample) 1988-08-05 1993-10-07
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
EP0950060A4 (en) 1996-12-02 2000-07-05 Dyad Pharmaceutical Corp COUNTERSTRAIN INHIBITION OF HUMAN ADHESION MOLECULES
RU2147240C1 (ru) * 1998-02-16 2000-04-10 Рязанский областной клинический кожно-венерологический диспансер Препарат для лечения длительно незаживающих инфицированных язв и ран
ES2498745T3 (es) * 1999-01-27 2014-09-25 Coda Therapeutics, Inc. Formulaciones que comprenden nucleótidos antisentido para conexinas
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US20050119211A1 (en) 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
JP2005509621A (ja) 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン ギャップ結合ならびにｅｄｈｆ
EA006860B1 (ru) 2002-01-29 2006-04-28 Уайт Композиции и способы модулирования гемиканалов коннексина
CA3059497A1 (en) * 2003-12-03 2005-06-16 Ocunexus Therapeutics, Inc. Antisense compounds targeted to connexins and methods of use thereof
DE102004027422A1 (de) 2004-06-04 2005-12-29 Boehringer Ingelheim Microparts Gmbh Vorrichtung zur Aufnahme von Blut und Abtrennung von Blutbestandteilen
ES2620363T3 (es) 2004-12-21 2017-06-28 Musc Foundation For Research Development Composiciones y métodos para promover la cicatrización de heridas y la regeneración tisular
JP5964538B2 (ja) 2005-02-03 2016-08-03 コーダ セラピューティクス， インコーポレイテッド 抗コネキシン化合物およびそれらの使用
US8247384B2 (en) 2006-11-15 2012-08-21 Coda Therapeutics, Inc. Methods and compositions for wound healing
CN101835476B (zh) 2006-12-11 2016-08-17 科达治疗公司 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
CN101970663A (zh) 2007-12-11 2011-02-09 科达治疗公司 受损伤口愈合的组合物和治疗
EP2628747A1 (en) 2007-12-11 2013-08-21 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cindy Qiu et al.Targeting Connexin43 Expression Accelerates the Rate of Wound Repair.《Current Biology》.2003,第13卷第1700页第12行至第33行. *

Also Published As

Publication number Publication date
AU2007333535A1 (en) 2008-06-19
US20120289579A1 (en) 2012-11-15
JP5911454B2 (ja) 2016-04-27
WO2008073479A2 (en) 2008-06-19
EP2543378A1 (en) 2013-01-09
KR20090118910A (ko) 2009-11-18
JP2010512404A (ja) 2010-04-22
JP2013173796A (ja) 2013-09-05
US20130143952A1 (en) 2013-06-06
KR101521306B1 (ko) 2015-05-18
DK2101791T3 (en) 2015-01-05
SI2101791T1 (sl) 2015-02-27
US20150315598A1 (en) 2015-11-05
WO2008073479A3 (en) 2008-08-07
US9637745B2 (en) 2017-05-02
JP5431949B2 (ja) 2014-03-05
CN103520197A (zh) 2014-01-22
EP2101791B1 (en) 2014-09-10
CN103520197B (zh) 2017-11-21
PT2101791E (pt) 2014-12-18
JP2015063565A (ja) 2015-04-09
RU2009126594A (ru) 2011-01-20
US20080242631A1 (en) 2008-10-02
RU2521329C2 (ru) 2014-06-27
AU2007333535B2 (en) 2014-04-17
US9029339B2 (en) 2015-05-12
ES2527131T3 (es) 2015-01-20
PL2101791T3 (pl) 2015-04-30
CN101835476A (zh) 2010-09-15
US8063023B2 (en) 2011-11-22
US8685940B2 (en) 2014-04-01
CA2672220A1 (en) 2008-06-19
EP2101791A2 (en) 2009-09-23
US20170240905A1 (en) 2017-08-24
BRPI0721094A2 (pt) 2014-02-11
HK1136213A1 (en) 2010-06-25
EP2543377A1 (en) 2013-01-09

Similar Documents

Publication Publication Date Title
CN101835476B (zh) 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
US20100279921A1 (en) Impaired wound healing compositions and treatments
US20110038920A1 (en) Wound healing compositions and treatments
US20110130710A1 (en) Treatment of abnormal or excessive scars
US20130184220A1 (en) Treatment of abnormal or excessive scars
AU2014204482B2 (en) Anticonnexin polynucleotides as impaired wound healing compositions
HK1136213B (en) Anticonnexin polynucleotides as impaired wound healing compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: American California

Patentee after: Medical Treatment Co Ltd

Address before: American California

Patentee before: Coda Therapeutics Inc.

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160817

Termination date: 20201211

CF01 Termination of patent right due to non-payment of annual fee